febuxostat + benzbromarone

Febuxostat + benzbromarone is a combination therapy investigated for the management of gout and gouty arthritis, particularly in patients with inadequate response to monotherapy. This dual-action regimen combines febuxostat, a potent, non-purine selective inhibitor of xanthine oxidase (XO), with benzbromarone, a uricosuric agent that inhibits the urate transporter 1 (URAT1). By simultaneously inhibiting the production of uric acid in the liver and promoting its excretion through the kidneys, the combination effectively lowers serum uric acid levels. Yuebei People’s Hospital has conducted clinical research evaluating the efficacy and safety of this combination, demonstrating its potential to achieve target urate levels more rapidly than single-agent treatments. While febuxostat is widely used globally, benzbromarone's use is restricted in some regions due to potential hepatotoxicity, though it remains a standard treatment in several Asian and European countries.

Other names

febuxostat and benzbromaronefebuxostat/benzbromarone